Product Name :
Protosappanin A
Description:
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.
CAS:
102036-28-2
Molecular Weight:
272.25
Formula:
C15H12O5
Chemical Name:
5, 14, 15-trihydroxy-8-oxatricyclo[10.4.0.0, ]hexadeca-1(16), 2, 4, 6, 12, 14-hexaen-10-one
Smiles :
OC1=CC2OCC(=O)CC3=CC(O)=C(O)C=C3C=2C=C1
InChiKey:
MUKYVRVYBBYJSI-UHFFFAOYSA-N
InChi :
InChI=1S/C15H12O5/c16-9-1-2-11-12-6-14(19)13(18)4-8(12)3-10(17)7-20-15(11)5-9/h1-2,4-6,16,18-19H,3,7H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.|Product information|CAS Number: 102036-28-2|Molecular Weight: 272.25|Formula: C15H12O5|Synonym:|PTA|Chemical Name: 5, 14, 15-trihydroxy-8-oxatricyclo[10.4.0.0, ]hexadeca-1(16), 2, 4, 6, 12, 14-hexaen-10-one|Smiles: OC1=CC2OCC(=O)CC3=CC(O)=C(O)C=C3C=2C=C1|InChiKey: MUKYVRVYBBYJSI-UHFFFAOYSA-N|InChi: InChI=1S/C15H12O5/c16-9-1-2-11-12-6-14(19)13(18)4-8(12)3-10(17)7-20-15(11)5-9/h1-2,4-6,16,18-19H,3,7H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Neflamapimod} medchemexpress|{Neflamapimod} Autophagy|{Neflamapimod} Technical Information|{Neflamapimod} In stock|{Neflamapimod} manufacturer|{Neflamapimod} Cancer} |Shelf Life: ≥12 months if stored properly.{{Baricitinib} MedChemExpress|{Baricitinib} Epigenetics|{Baricitinib} Protocol|{Baricitinib} Formula|{Baricitinib} custom synthesis|{Baricitinib} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Protosappanin A (PTA: 12.5, 25, 50 μM, 24 hours) significantly inhibits the production of TNF-α and IL-1β in LPS-activated BV2 microglia.PMID:33063628 And the mRNA expressions of IL-6, IL-1β, and MCP-1 are reduced by PTA in a dose-dependent manner in BV2 microglial cell line. Protosappanin A (PTA: 12.5, 25, 50 μM, 24 hours) suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3, as well as STAT3 nuclear translocation against LPS treatment. Protosappanin A (PTA: 12.5, 25, 50 μM, 24 hours) shows obvious effect on disturbing the interaction of transmembrane protein CD14 with Toll-like receptor-4, resulting in the inhibition of NF-κB-dependent oxidative and nitrative stress in LPS-induced BV2 microglia.|References:|Wang LC, et al. Protosappanin A exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Chin J Nat Med. 2017 Sep;15(9):674-679.Zeng KW, et al. Protosappanin A inhibits oxidative and nitrative stress via interfering the interaction of transmembrane protein CD14 with Toll-like receptor-4 in lipopolysaccharide-induced BV-2 microglia. Int Immunopharmacol, 2012, 14(4): 558- 569.Products are for research use only. Not for human use.|